Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
University Hospital, Bordeaux
150 participants
Sep 30, 2021
INTERVENTIONAL
Conditions
Summary
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
1 ml of cerebro-spinal fluid
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04798651